Amylyx Pharmaceuticals (NASDAQ:AMLX) Releases Earnings Results

Amylyx Pharmaceuticals (NASDAQ:AMLX) posted its earnings results on Thursday. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.03), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• LUCIDITY top-line data is expected in late August or early September 2026 after the final participant completed the 16-week study period; database cleaning and locking are still underway, and management remains blinded to the results.
• Amylyx reported $250.8 million in cash and marketable securities at quarter-end and expects its cash runway to extend into 2028, covering anticipated avexitide milestones, including a potential 2027 launch.
• Commercial preparations are advancing ahead of a potential avexitide approval, including field medical deployment, key commercial hires, an HCP and patient education campaign, and plans to target treatment centers with concentrated PBH populations.
• Management estimates approximately 160,000 U.S. patients have post-bariatric hypoglycemia and cites high endocrinologist intent to treat with an approved therapy; a dedicated ICD-10 code becomes effective October 1, 2026, potentially improving recognition and tracking of the condition.
• Q2 operating expenses rose 7% year over year to $45.7 million, driven partly by higher legal costs, including a one-time charge, and increased commercial investment; avexitide’s approval, label breadth, and launch timing remain dependent on the pending phase III data and FDA review.

Amylyx Pharmaceuticals Trading Down 5.7%

AMLX stock opened at $22.82 on Friday. The stock has a market cap of $2.54 billion, a P/E ratio of -15.96 and a beta of -0.21. Amylyx Pharmaceuticals has a twelve month low of $7.48 and a twelve month high of $24.60. The company’s 50 day moving average is $17.36 and its two-hundred day moving average is $15.76.

Analyst Ratings Changes

Several research analysts have recently commented on AMLX shares. Citigroup lifted their price target on Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. HC Wainwright reiterated a “buy” rating and issued a $34.00 target price on shares of Amylyx Pharmaceuticals in a report on Monday, June 8th. Mizuho increased their price target on shares of Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an “outperform” rating in a research note on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday. Finally, Wall Street Zen cut Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Amylyx Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $25.38.

Insider Activity

In related news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $18.32, for a total value of $274,800.00. Following the transaction, the insider directly owned 194,090 shares of the company’s stock, valued at $3,555,728.80. This trade represents a 7.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 10.90% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. increased its position in Amylyx Pharmaceuticals by 54.5% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock worth $56,408,000 after buying an additional 3,102,395 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 0.4% in the second quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company’s stock valued at $50,654,000 after acquiring an additional 28,017 shares during the period. TCG Crossover Management LLC boosted its holdings in shares of Amylyx Pharmaceuticals by 5.0% in the third quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock valued at $84,853,000 after acquiring an additional 300,000 shares during the period. Janus Henderson Group PLC grew its position in shares of Amylyx Pharmaceuticals by 76.1% during the fourth quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company’s stock worth $53,992,000 after acquiring an additional 1,929,639 shares during the last quarter. Finally, Millennium Management LLC grew its position in shares of Amylyx Pharmaceuticals by 418.6% during the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock worth $10,910,000 after acquiring an additional 2,487,617 shares during the last quarter. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.